Detalhe da pesquisa
1.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27717303
2.
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 168(1): 127-134, 2018 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-29164421
3.
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 167(3): 659-669, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29058175
4.
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
J Clin Oncol
; 30(31): 3841-7, 2012 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22987083